
    
      A randomized, double-blind, placebo-controlled clinical trial its going to carry out in 24
      patients with a diagnosis of metabolic syndrome in accordance with the International Diabetes
      Federation (IDF). Waist circumference, glucose, insulin levels, lipid profile, creatinine and
      acid uric are going to be load after a 75 g of dextrose load.

      12 patients will receive Forxiga (dapagliflozin), 10 mg, one per day before breakfast during
      3 months.

      The remaining 12 patients will receive placebo at the same dose.

      There will be calculated Area Under the Curve of glucose and insulin, total insulin secretion
      (insulinogenic index), first-phase of insulin secretion (Stumvoll index) and insulin
      sensitivity (Matsuda index).

      This protocol it's already approved by the local ethics committee and written informed
      consent it's going to be obtained from all volunteers.

      Results will be presented as mean and standard deviation. Intra and inter group differences
      are going to be tested using the Wilcoxon signed-rank and Mann-Whitney U-test respectively;
      pâ‰¤0.05 it's going to be considered significant.
    
  